Mon, Sep 09, 2013 - Page 13 News List

FEATURE: Investors in breast and colorectal cancer drugs sought

BUSINESS MODEL:Revenue will be made by offering manufacturing and research services to other drugmakers to make the recombinant proteins and biosimilar drugs

By Camaron Kao  /  Staff reporter

He estimated the market values for both drugs are about US$6 billion each. To fund its capital spending, and research and development, the company plans to raise another NT$450 million to NT$600 million in the second half of next year. The company is looking for foreign investors to participate in the fund-raising, Liu said.

However, EirGenix is not without possible competitors. Mycenax Biotech Inc (永昕生醫) is building a factory with a capacity of 2,000 liters, while Amaran Biotechnology Inc (潤雅生技) is constructing a factory for the manufacture of Botox, which is widely used in cosmetic surgery. PharmaEssentia Corp (藥華醫藥) has a factory to make 1 million units of drugs a year.

This story has been viewed 2199 times.

Comments will be moderated. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned.

TOP top